Zydus' sales up by 21% on formulations, US growth
This article was originally published in Scrip
Zydus Cadila has reported a 21% increase in net sales to Rs11.06 billion ($249.4 million) for the second quarter ended 30 September compared with the same quarter in the previous year, backed by strong growth in its formulations and US businesses. Net profit rose by 30% to Rs1.70 billion.
You may also be interested in...
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.
ISCR conference hears how artificial intelligence and machine learning can address challenges in clinical medicine, especially for cancer, and also optimize clinical trials.